ES2305253T3 - Combinacion de docetaxel y flavopiridol. - Google Patents
Combinacion de docetaxel y flavopiridol. Download PDFInfo
- Publication number
- ES2305253T3 ES2305253T3 ES02737950T ES02737950T ES2305253T3 ES 2305253 T3 ES2305253 T3 ES 2305253T3 ES 02737950 T ES02737950 T ES 02737950T ES 02737950 T ES02737950 T ES 02737950T ES 2305253 T3 ES2305253 T3 ES 2305253T3
- Authority
- ES
- Spain
- Prior art keywords
- flavopyridol
- taxotere
- combination
- administered
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title claims abstract description 37
- 229960003668 docetaxel Drugs 0.000 title description 11
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 title 1
- 229950010817 alvocidib Drugs 0.000 title 1
- 229940063683 taxotere Drugs 0.000 claims abstract description 28
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 230000001613 neoplastic effect Effects 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 6
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 239000000470 constituent Substances 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 201000005296 lung carcinoma Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 108091007914 CDKs Proteins 0.000 description 5
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 5
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 4
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102000016736 Cyclin Human genes 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- 229940123237 Taxane Drugs 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 201000008274 breast adenocarcinoma Diseases 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 241000202349 Taxus brevifolia Species 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000004913 chyme Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- -1 diterpene compounds Chemical class 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000025090 microtubule depolymerization Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000027291 mitotic cell cycle Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27794801P | 2001-03-23 | 2001-03-23 | |
| US277948P | 2001-03-23 | ||
| US30269201P | 2001-07-05 | 2001-07-05 | |
| US302692P | 2001-07-05 | ||
| US33491601P | 2001-12-04 | 2001-12-04 | |
| US334916P | 2001-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2305253T3 true ES2305253T3 (es) | 2008-11-01 |
Family
ID=27402954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02737950T Expired - Lifetime ES2305253T3 (es) | 2001-03-23 | 2002-03-22 | Combinacion de docetaxel y flavopiridol. |
Country Status (33)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003217982A1 (en) * | 2002-03-06 | 2003-09-22 | The Medical Research And Education Trust | Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol |
| AU2003287081A1 (en) * | 2002-10-16 | 2004-05-04 | Ilex Products, Inc. | Clofarabine and taxane chemotherapy combination |
| EP1558242B1 (en) * | 2002-11-06 | 2008-12-24 | Cyclacel Limited | Combination comprising docetaxel and a cdk inhibitor |
| ES2390237T3 (es) * | 2006-02-10 | 2012-11-07 | Nerviano Medical Sciences S.R.L. | Combinaciones que comprenden un inhibidor de cdk y un anticuerpo anti-factor de crecimiento o un agente antimitótico |
| BR112013012313A2 (pt) * | 2010-11-19 | 2019-09-24 | Piramal Enterprises Limited | combinação farmacêutica de paclitaxel e um inibidor de cdk |
| ME03589B (me) | 2011-04-01 | 2020-07-20 | Astrazeneca Ab | Terapeutski tretman |
| MX367640B (es) | 2011-11-30 | 2019-08-29 | Astrazeneca Ab | Tratamiento combinado del cáncer. |
| AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2601675B1 (fr) * | 1986-07-17 | 1988-09-23 | Rhone Poulenc Sante | Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent |
| MX9102128A (es) * | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| EP0888458A4 (en) * | 1996-02-20 | 2004-05-06 | Sloan Kettering Institutefor C | COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER |
-
2002
- 2002-03-21 UY UY27220A patent/UY27220A1/es not_active Application Discontinuation
- 2002-03-21 US US10/101,947 patent/US20020182204A1/en not_active Abandoned
- 2002-03-22 AU AU2002312815A patent/AU2002312815B2/en not_active Ceased
- 2002-03-22 TW TW091105567A patent/TWI355935B/zh not_active IP Right Cessation
- 2002-03-22 ES ES02737950T patent/ES2305253T3/es not_active Expired - Lifetime
- 2002-03-22 SI SI200230711T patent/SI1372652T1/sl unknown
- 2002-03-22 CN CNA028070380A patent/CN1498107A/zh active Pending
- 2002-03-22 IL IL15805802A patent/IL158058A0/xx unknown
- 2002-03-22 KR KR1020037012338A patent/KR100879712B1/ko not_active Expired - Fee Related
- 2002-03-22 SK SK1169-2003A patent/SK287481B6/sk not_active IP Right Cessation
- 2002-03-22 AR ARP020101061A patent/AR034222A1/es unknown
- 2002-03-22 BR BR0208221-7A patent/BR0208221A/pt not_active Application Discontinuation
- 2002-03-22 PE PE2002000230A patent/PE20020907A1/es not_active Application Discontinuation
- 2002-03-22 NZ NZ527655A patent/NZ527655A/xx not_active IP Right Cessation
- 2002-03-22 AT AT02737950T patent/ATE395917T1/de active
- 2002-03-22 EP EP02737950A patent/EP1372652B1/en not_active Expired - Lifetime
- 2002-03-22 CA CA002441441A patent/CA2441441C/en not_active Expired - Fee Related
- 2002-03-22 PT PT02737950T patent/PT1372652E/pt unknown
- 2002-03-22 HR HR20030766A patent/HRPK20030766B3/xx not_active IP Right Cessation
- 2002-03-22 DE DE60226710T patent/DE60226710D1/de not_active Expired - Lifetime
- 2002-03-22 PL PL367702A patent/PL206118B1/pl not_active IP Right Cessation
- 2002-03-22 MX MXPA03007743A patent/MXPA03007743A/es active IP Right Grant
- 2002-03-22 JP JP2002574997A patent/JP2004521140A/ja active Pending
- 2002-03-22 ME MEP-164/08A patent/MEP16408A/xx unknown
- 2002-03-22 RS YUP-695/03A patent/RS50681B/sr unknown
- 2002-03-22 CZ CZ20032551A patent/CZ301423B6/cs not_active IP Right Cessation
- 2002-03-22 WO PCT/EP2002/004083 patent/WO2002076484A2/en not_active Ceased
- 2002-03-22 DK DK02737950T patent/DK1372652T3/da active
- 2002-03-22 EA EA200301053A patent/EA007815B1/ru not_active IP Right Cessation
- 2002-03-22 HU HU0303589A patent/HU229258B1/hu not_active IP Right Cessation
-
2003
- 2003-09-16 NO NO20034124A patent/NO332441B1/no not_active IP Right Cessation
- 2003-09-22 ZA ZA2003/07381A patent/ZA200307381B/en unknown
- 2003-09-22 IL IL158058A patent/IL158058A/en not_active IP Right Cessation
-
2006
- 2006-01-27 US US11/341,840 patent/US20060128640A1/en not_active Abandoned
-
2008
- 2008-08-11 CY CY20081100843T patent/CY1110449T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2622559T3 (es) | Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico | |
| Malhotra et al. | Classical chemotherapy: mechanisms, toxicities and the therapeutc window | |
| Choy | Taxanes in combined modality therapy for solid tumors | |
| ES2390237T3 (es) | Combinaciones que comprenden un inhibidor de cdk y un anticuerpo anti-factor de crecimiento o un agente antimitótico | |
| Strimpakos et al. | Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness? | |
| ES2441593T3 (es) | Composiciones para estimular la actividad de terapias anticáncer | |
| Nabell et al. | Docetaxel with concurrent radiotherapy in head and neck cancer | |
| Tishler et al. | An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies | |
| JP2009536956A (ja) | 抗癌治療法 | |
| RU2005126819A (ru) | Усовершенствованное лечение опухолей | |
| Menon et al. | Antitumor activity of cryptophycins: effect of infusion time and combination studies | |
| AU2002312815B2 (en) | Combination of a taxane and a cyclin-dependent kinase inhibitor | |
| EP3445347A1 (en) | Chemotherapy improvements | |
| AU2002312815A1 (en) | Combination of a taxane and a cyclin-dependent kinase inhibitor | |
| Di Cosimo et al. | Docetaxel in advanced gastric cancer review of the main clinical trials | |
| Bekaii-Saab et al. | Preclinical experience with docetaxel in gastrointestinal cancers | |
| Georgoulias et al. | Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer | |
| Le Chevalier | Gemcitabine and pemetrexed (Alimta) in thoracic cancers: Present and future perspectives. Introduction and current controversies | |
| Cosimo et al. | Docetaxel in Advanced Gastric Cancer. | |
| Daud et al. | 494 A phase I trial of SCH900776, a selective inhibitor of checkpoint kinase CHK-1, in combination with Gemcitabine in advanced solid tumors | |
| Verschraegen et al. | 714 POSTER Phase I tolerability/safety of sunitinib in combination with capecitabine in patients (pts) with advanced solid tumors | |
| Giannios et al. | 713 POSTER Molecularly targeted immunochemotherapeutic formulation (SEVINA) composed of pegylated trispecific disulfide linked Fv (sdFv) targeting epitopes of EGFR, PTHrP and RANKL conjugated covalently with SATA to vinorelbine eradicated osteolytic metastases of multiple myeloma inhibiting proliferation of tumor associated and bone microvascular endothelial cells inducing ADCC, AMP and type I, II, III PCD | |
| Linderholm et al. | Weekly taxanes A leap forward or a minute progress? | |
| TH102680A (th) | การใช้โดซีแทกเซล/ดอกโซรูบิซิน/ไซโคลฟอสฟาไมด์ ในการรักษาแบบเสริม |